Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 43/72 ]
NASDAQ | Common Stock
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States.
It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.
The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy.
The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth.
Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal healt
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -0.07 Increased by +22.22% | -0.06 Decreased by -16.67% |
| Mar 28, 24 | -0.06 Increased by +68.42% | -0.10 Increased by +40.00% |
| Nov 9, 23 | -0.09 Decreased by -12.50% | -0.10 Increased by +10.00% |
| Aug 10, 23 | -0.10 Decreased by -2.18 K% | -0.10 |
| May 11, 23 | -0.09 Increased by +10.00% | -0.10 Increased by +10.00% |
| Mar 30, 23 | -0.19 Decreased by -5.56% | -0.14 Decreased by -35.71% |
| Nov 10, 22 | -0.08 Increased by +55.56% | -0.12 Increased by +33.33% |
| Aug 9, 22 | 0.00 Increased by +102.67% | -0.06 Increased by +108.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 1.00 M Increased by +N/A% | -8.30 M Decreased by -20.26% | Decreased by -829.91% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -8.76 M Decreased by -2.22 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -7.70 M Increased by +8.27% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 10.00 B Increased by +N/A% | 421.69 M Increased by +4.52 K% | Increased by +4.22% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -6.90 M Increased by +45.52% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 10.00 M Increased by +N/A% | 414.00 K Increased by +104.52% | Increased by +4.14% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -8.40 M Decreased by -14.65% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -9.54 M Decreased by -13.04% | Decreased by N/A% Decreased by N/A% |